

Please cite this article in press as: Muller CL et al. The serotonin system in autism spectrum disorder: From biomarker to animal models. *Neuroscience* (2015), <http://dx.doi.org/10.1016/j.neuroscience.2015.11.010>

Neuroscience xxx (2015) xxx–xxx

REVIEW

THE SEROTONIN SYSTEM IN AUTISM SPECTRUM DISORDER: FROM BIOMARKER TO ANIMAL MODELS

C. L. MULLER,^a A. M. J. ANACKER^b AND J. VEENSTRA-VANDERWEELE^{b,c,*}

^a Vanderbilt Brain Institute, Vanderbilt University, 465 21st Avenue South, Nashville, TN 37232, USA

^b Department of Psychiatry, Columbia University, and New York State Psychiatric Institute, 1051 Riverside Drive, Mail Unit 78, New York, NY 10032, USA

^c Center for Autism and the Developing Brain, New York Presbyterian Hospital, 21 Bloomingdale Road, White Plains, NY 10605, USA

Abstract—Elevated whole-blood serotonin, or hyperserotonemia, was the first biomarker identified in autism spectrum disorder (ASD) and is present in more than 25% of affected children. The serotonin system is a logical candidate for involvement in ASD due to its pleiotropic role across multiple brain systems both dynamically and across development. Tantalizing clues connect this peripheral biomarker with changes in brain and behavior in ASD, but the contribution of the serotonin system to ASD pathophysiology remains incompletely understood. Studies of whole-blood serotonin levels in ASD and in a large founder population indicate greater heritability than for the disorder itself and suggest an association with recurrence risk. Emerging data from both neuroimaging and postmortem samples also indicate changes in the brain serotonin system in ASD. Genetic linkage and association studies of both whole-blood serotonin levels and of ASD risk point to the chromosomal region containing the serotonin transporter (SERT) gene in males but not in females. In ASD families with evidence of linkage to this region, multiple rare SERT amino acid variants lead to a convergent increase in serotonin uptake in cell models. A knock-in mouse model of one of these variants, SERT Gly56Ala, recapitulates the hyperserotonemia biomarker and shows increased brain serotonin clearance, increased serotonin receptor

sensitivity, and altered social, communication, and repetitive behaviors. Data from other rodent models also suggest an important role for the serotonin system in social behavior, in cognitive flexibility, and in sensory development. Recent work indicates that reciprocal interactions between serotonin and other systems, such as oxytocin (OT), may be particularly important for social behavior. Collectively, these data point to the serotonin system as a prime candidate for treatment development in a subgroup of children defined by a robust, heritable biomarker.

This article is part of a Special Issue entitled: Neuropsychiatric Disease. © 2015 Published by Elsevier Ltd. on behalf of IBRO.

Key words: genetic, monoamine, reuptake, platelet, neurodevelopment, multisensory.

	Contents	
Introduction		00 16
Brief overview of the serotonin system		00 17
Serotonin and neurodevelopment		00 18
Hyperserotonemia: the first biomarker in ASD		00 19
Potential mechanisms of hyperserotonemia		00 20
The central serotonin system in ASD		00 21
Genetic linkage and association studies of <i>SLC6A4</i> in ASD		00 22
The SERT Ala56 mouse as a model of ASD risk and hyperserotonemia		00 23
Other rodent models of altered 5-HT function relevant to ASD		00 24
Mouse models of ASD risk with abnormal 5-HT		00 25
Interplay between the serotonin and oxytocin systems		00 26
Next steps to understand the contribution of the serotonin system to ASD		00 27
Biomedical conflicts of interest		00 28
Acknowledgments		00 29
References		00 30

*Correspondence to: J. Veenstra-VanderWeele, Department of Psychiatry, Columbia University, and New York State Psychiatric Institute, 1051 Riverside Drive, Mail Unit 78, New York, NY 10025, USA. Tel: + 1-646-774-5251 (office).

E-mail addresses: christopher.l.muller@vanderbilt.edu (C. L. Muller), aanacke@nyspi.columbia.edu (A. M. J. Anacker), veenstr@nyspi.columbia.edu (J. Veenstra-VanderWeele).

Abbreviations: 5-HIAA, 5-hydroxyindoleacetic acid; ASD, autism spectrum disorder; *ITGB3*, integrin β 3 subunit gene; MAOA, mitochondrial bound protein monoamine oxidase A; MAPK, mitogen-activated protein kinase; MDMA, 3,4-methylenedioxymethamphetamine; NAS, N-acetylserotonin; OCD, obsessive-compulsive disorder; OT, oxytocin; PKG, protein kinase G; SERT, serotonin transporter; *SLC6A4*, serotonin transporter gene; SSRIs, serotonin reuptake inhibitors; TPH, tryptophan hydroxylase.

<http://dx.doi.org/10.1016/j.neuroscience.2015.11.010>

0306-4522/© 2015 Published by Elsevier Ltd. on behalf of IBRO.

INTRODUCTION

Findings from multiple domains of research have implicated the serotonin system in autism spectrum disorder (ASD). Initial findings more than 50 years ago identified elevated whole-blood serotonin levels, termed hyperserotonemia, in a subset of children with autism. Since then, work on the serotonin system in ASD has extended intermittently as new tools have become

2

C. L. Muller et al. / Neuroscience xxx (2015) xxx–xxx


47 available, from pharmacology to genetics to
48 neuroimaging. Emerging findings, driven largely by
49 advances in mouse models, point to the importance of
50 serotonin for social function, repetitive behavior, and
51 sensory development. With the increasing recognition of
52 heterogeneity in ASD, biological markers will play an
53 important role in identifying subsets of children who are
54 more likely to share common risk or benefit from the
55 same treatments. The combination of a robust
56 biomarker with a rich understanding of serotonin
57 neurobiology suggests that the serotonin system is
58 particularly ripe for treatment development in a subset
59 of children with ASD.

BRIEF OVERVIEW OF THE SEROTONIN SYSTEM

62 For millions of years, serotonin (5-hydroxytryptamine,
63 5-HT) has existed as a signaling molecule across
64 phylogeny (Hay-Schmidt, 2000). It is produced from the
65 essential amino acid, tryptophan, via a two-step synthetic
66 pathway. In the first step, tryptophan is converted to

5-hydroxytryptophan (5-HTP) by the rate-limiting enzyme
in 5-HT synthesis, tryptophan hydroxylase (TPH) (Fig. 1).
There are two isoforms of tryptophan hydroxylase, TPH1
and TPH2, which are primarily responsible for 5-HT
synthesis in the periphery and central nervous system
(CNS), respectively (Lovenberg et al., 1967; Walther
et al., 2003). In the final step, the intermediate product,
5-HTP, is converted to 5-HT by aromatic acid
decarboxylase (AADC). Degradation of 5-HT primarily
occurs by the mitochondrial bound protein monoamine
oxidase A (MAOA), leading to the production of the
metabolite, 5-hydroxyindoleacetic acid (5-HIAA). Importantly,
serotonin also serves as an intermediate substrate
for melatonin synthesis.

Though more recognized for its role as a
neurotransmitter, the vast majority of 5-HT produced in
the body is located in the periphery. Specifically,
enterochromaffin cells that line the lumen of the
gastrointestinal tract are the primary source of
peripheral 5-HT, which is then taken up by platelets as
they pass through the enteric circulation (Anderson



© 2000-2015 QIAGEN. All rights reserved.

Fig. 1. Overview of the serotonin system. This cartoon depicts the serotonin synthesis, release, reuptake, and degradation, as well as the canonical roles of a subset of serotonin receptors. TPH = tryptophan hydroxylase. AADC = aromatic acid decarboxylase. VMAT = vesicular monoamine transporter. SERT = serotonin transporter. MAO = monoamine oxidase. 5HT1–7 = serotonin receptor subgroups (oval shape) and individual receptors (goblet shape). Figure created using Ingenuity Pathway Analysis (Qiagen, Valencia, CA).

Download English Version:

<https://daneshyari.com/en/article/6271152>

Download Persian Version:

<https://daneshyari.com/article/6271152>

[Daneshyari.com](https://daneshyari.com)